✦ LIBER ✦

Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase-Positive, Non-Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?

✍ Scribed by Kelly, R. J.; Hillner, B. E.; Smith, T. J.

Book ID: 126527062
Publisher: American Society of Clinical Oncology
Year: 2014
Tongue: English
Weight: 59 KB
Volume: 32
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2013.54.6002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Crizotinib: a guide to its use in previo

Crizotinib: a guide to its use in previously treated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer in the EU

✍ Hines, Mary; Lyseng-Williamson, Katherine A.; Curran, Monique P. 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 229 KB

U.S. Food and Drug Administration Approv

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

✍ Malik, S. M.; Maher, V. E.; Bijwaard, K. E.; Becker, R. L.; Zhang, L.; Tang, S. 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 433 KB